Correlation of C0 and C2 Levels With Cyclosporine Side Effects in Kidney Transplantation

Transplantation Proceedings

Volumn 41, Issue 6, 2009, Pages 2328-2331

  Rodrigo, E ^a   Ruiz, J C ^a   Angeles de Cos, M ^a   Ruiz, J ^a   Gago, M ^a   Pinera C ^a   Sanchez B ^a   Gonzalez Cotorruelo J ^a   Gomez Alamillo C ^a   Arias, M ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATININE; CYCLOSPORIN A; GLUCOSE; POTASSIUM; TRIACYLGLYCEROL; URIC ACID;

ACUTE GRAFT REJECTION; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PULSE PRESSURE; ROC CURVE; SODIUM URINE LEVEL; SYSTOLIC HYPERTENSION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

AREA UNDER CURVE; BLOOD PRESSURE; CHOLESTEROL; CREATININE; CYCLOSPORINE; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POTASSIUM; PULSE; RETROSPECTIVE STUDIES; ROC CURVE; SODIUM; URIC ACID;

EID: 68949198049     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.155     Document Type: Article

References (12)

1. Knight S.R., and Morris P.J. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 83 (2007) 1525
2. Mahalati K., Belitsky P., Sketris I., et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68 (1999) 55
3. Keown P., and Canadian Neoral Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 72 (2001) 1024
4. Pescovitz M.D., Barbeito R., and Simulect US01 Study Group. Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant 16 (2002) 378
5. Chueh S.C., and Kahan B.D. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression and prognosis. Transplantation 76 (2003) 375
6. Kuster G.M., Drexel H., Bleisch J.A., et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 57 (1994) 1479
7. Soylu A., Kavkcu S., Türkmen M.A., et al. Correlation of C0 and C2 levels with lipid profiles in adolescent renal transplant recipients in the early and late posttransplant periods. Transplant Proc 38 (2006) 1286
8. Cardinal H., Barama A.A., Fradet V., et al. Total cholesterol correlates with cyclosporine C2 levels in kidney transplant recipients under maintenance immunosuppression. Transplant Proc 36 suppl 2S (2004) 448
9. Kahan B.D., Flechner S.M., Lorber M.I., et al. Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. Transplantation 43 (1987) 197
10. Mahalati K., Belitsky P., West K., et al. Approaching the therapeutic window for cyclosporine in kidney transplantation. J Am Soc Nephrol 12 (2001) 828
11. Clive D.M. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 11 (2000) 974
12. Marcén R., Gallego N., Orofino L., et al. Impairment of tubular secretion of urate in renal transplant patients on cyclosporine. Nephron 70 (1995) 307